Literature DB >> 23546814

Early cardiac changes in children with anderson-fabry disease.

Stepan Havranek1, Ales Linhart, Zuzana Urbanova, Uma Ramaswami.   

Abstract

OBJECTIVE: Limited evidence is available about the early cardiac manifestation of Fabry disease (FD) in children. We aimed to evaluate cardiac involvement in children with FD by analysing serial structural and electrocardiographic changes.
METHODS: The data were acquired from 22 children with FD [11 males; median age 9.8 (ranging 2.5-16) years]. Seven patients (5 males) were on enzyme replacement therapy (ERT) with Agalasidase alpha. Echocardiography, ECG and 24-h ECG monitoring recordings were acquired during routine annual clinical controls. ECG data were compared to a group of age-and gender-matched controls.
RESULTS: At baseline, ECG and ECHO parameters of left ventricular mass were similar in both males and females. Three boys (all were on ERT) developed left ventricular hypertrophy (LVH) during two-year follow-up. The progression to LVH was accompanied by the appearance of frequent ventricular premature beats in two cases and supraventricular premature beats (SPBs) with T wave inversion in one case. T wave inversion and SPBs were detected in two younger relatives of a patient with LVH, in the absence of detectable LVH. Seven out of 22 patients had T wave abnormalities. Five of them were males (p = 0.03) all carrying the N215S mutation (p = 0.03). At baseline, median PR intervals were prolonged in FD subjects compared to controls [143 (122-177) vs. 122 (82-165) ms; p < 0.0001].
CONCLUSIONS: Cardiac complications of FD become apparent in childhood as subtle changes with slow but detectable progression over time, with males more frequently affected than females. Progression of LVH was apparent in three children despite ERT.

Entities:  

Year:  2013        PMID: 23546814      PMCID: PMC3755562          DOI: 10.1007/8904_2013_222

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  45 in total

Review 1.  The normal ECG in childhood and adolescence.

Authors:  David F Dickinson
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

2.  Onset and progression of the Anderson-Fabry disease related cardiomyopathy.

Authors:  Christoph Kampmann; Ales Linhart; Frank Baehner; Tomas Palecek; Christiane M Wiethoff; Elke Miebach; Catharina Whybra; Andreas Gal; Jan Bultas; Michael Beck
Journal:  Int J Cardiol       Date:  2008-06-24       Impact factor: 4.164

3.  Aortic remodelling in Fabry disease.

Authors:  Frédéric Barbey; Salah D Qanadli; Christoph Juli; Noureddine Brakch; Tomás Palacek; Elena Rizzo; Xavier Jeanrenaud; Boris Eckhardt; Ales Linhart
Journal:  Eur Heart J       Date:  2009-10-21       Impact factor: 29.983

4.  Cardiovascular events in patients with fabry disease natural history data from the fabry registry.

Authors:  Manesh R Patel; Franco Cecchi; Marta Cizmarik; Ilkka Kantola; Ales Linhart; Kathy Nicholls; Jörg Strotmann; Jose Tallaj; Thi Chien Tran; Michael L West; Dana Beitner-Johnson; Ademola Abiose
Journal:  J Am Coll Cardiol       Date:  2011-03-01       Impact factor: 24.094

5.  Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Authors:  A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke
Journal:  Lancet       Date:  2009-12-12       Impact factor: 79.321

Review 6.  The pediatric electrocardiogram. Part I: Age-related interpretation.

Authors:  Matthew O'Connor; Nancy McDaniel; William J Brady
Journal:  Am J Emerg Med       Date:  2008-02       Impact factor: 2.469

7.  Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease.

Authors:  J Mehta; N Tuna; J H Moller; R J Desnick
Journal:  Am Heart J       Date:  1977-06       Impact factor: 4.749

8.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

9.  [Fabry disease: demographic data since introduction of enzyme replacement therapy].

Authors:  M Cybulla; K Walter; H P Neumann; U Widmer; M Schärer; G Sunder-Plassmann; T Jansen; A Rolfs; M Beck
Journal:  Dtsch Med Wochenschr       Date:  2007-07-05       Impact factor: 0.628

10.  Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.

Authors:  P M Elliott; H Kindler; J S Shah; B Sachdev; O E Rimoldi; R Thaman; M T Tome; W J McKenna; P Lee; P G Camici
Journal:  Heart       Date:  2005-08-05       Impact factor: 5.994

View more
  7 in total

1.  Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.

Authors:  Maarten Arends; Christoph Wanner; Derralynn Hughes; Atul Mehta; Daniel Oder; Oliver T Watkinson; Perry M Elliott; Gabor E Linthorst; Frits A Wijburg; Marieke Biegstraaten; Carla E Hollak
Journal:  J Am Soc Nephrol       Date:  2016-12-15       Impact factor: 10.121

Review 2.  Fabry disease in infancy and early childhood: a systematic literature review.

Authors:  Dawn A Laney; Dawn S Peck; Andrea M Atherton; Linda P Manwaring; Katherine M Christensen; Suma P Shankar; Dorothy K Grange; William R Wilcox; Robert J Hopkin
Journal:  Genet Med       Date:  2014-09-18       Impact factor: 8.822

Review 3.  Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN).

Authors:  Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

4.  Cardiac Phenotype of Prehypertrophic Fabry Disease.

Authors:  Sabrina Nordin; Rebecca Kozor; Shanat Baig; Amna Abdel-Gadir; Katia Medina-Menacho; Stefania Rosmini; Gabriella Captur; Michel Tchan; Tarekegn Geberhiwot; Elaine Murphy; Robin Lachmann; Uma Ramaswami; Nicola C Edwards; Derralynn Hughes; Richard P Steeds; James C Moon
Journal:  Circ Cardiovasc Imaging       Date:  2018-06       Impact factor: 7.792

Review 5.  Pediatric Restrictive Cardiomyopathies.

Authors:  Raffaello Ditaranto; Angelo Giuseppe Caponetti; Valentina Ferrara; Vanda Parisi; Matteo Minnucci; Chiara Chiti; Riccardo Baldassarre; Federico Di Nicola; Simone Bonetti; Tammam Hasan; Luciano Potena; Nazzareno Galiè; Luca Ragni; Elena Biagini
Journal:  Front Pediatr       Date:  2022-01-25       Impact factor: 3.418

6.  Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.

Authors:  Frits A Wijburg; Bernard Bénichou; Daniel G Bichet; Lorne A Clarke; Gabriela Dostalova; Alejandro Fainboim; Andreas Fellgiebel; Cassiano Forcelini; Kristina An Haack; Robert J Hopkin; Michael Mauer; Behzad Najafian; C Ronald Scott; Suma P Shankar; Beth L Thurberg; Camilla Tøndel; Anna Tylki-Szymańska; Uma Ramaswami
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

7.  Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study.

Authors:  Dominique P Germain; Eva Brand; Alessandro Burlina; Franco Cecchi; Scott C Garman; Judy Kempf; Dawn A Laney; Aleš Linhart; László Maródi; Kathy Nicholls; Alberto Ortiz; Federico Pieruzzi; Suma P Shankar; Stephen Waldek; Christoph Wanner; Ana Jovanovic
Journal:  Mol Genet Genomic Med       Date:  2018-04-12       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.